Secondary Logo

Journal Logo

Most Popular Articles

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

van der Wouden, Cathelijne H.; Böhringer, Stefan; Cecchin, Erika; More

Pharmacogenetics and Genomics. 30(6):131-144, August 2020.

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria

St Jean, Pamela L.; Koh, Gavin C.K.W.; Breton, John J.; More

Pharmacogenetics and Genomics. 30(7):161-165, September 2020.

Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes

Tshabalala, Sibongile; Choudhury, Ananyo; Beeton-Kempen, Natasha; More

Pharmacogenetics and Genomics. 29(7):167-178, September 2019.

Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population

Tempark, Therdpong; Satapornpong, Patompong; Rerknimitr, Pawinee; More

Pharmacogenetics and Genomics. 27(12):429-437, December 2017.

Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients

Gómez-Bravo, Miguel A.; Apellaniz-Ruiz, María; Salcedo, Magdalena; More

Pharmacogenetics and Genomics. 28(2):41-48, February 2018.

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics

Chan, Sze Ling; Samaranayake, Nilakshi; Ross, Colin J.D.; More

Pharmacogenetics and Genomics. 26(1):28-39, January 2016.

A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Lonjou, Christine; Borot, Nicolas; Sekula, Peggy; More

Pharmacogenetics and Genomics. 18(2):99-107, February 2008.

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

Iulio, Julia di; Fayet, Aurélie; Arab-Alameddine, Mona; More

Pharmacogenetics and Genomics. 19(4):300-309, April 2009.

Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon

Ferreira, Guilherme Motta Antunes; Ribeiro Elias, Anna Beatriz; Nascimento, Joabi; More

Pharmacogenetics and Genomics. 30(8):184-189, October 2020.

The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation

Nenonen, Hannah A.; Lindgren, Ida A.; Prahl, Alexandra S.; More

Pharmacogenetics and Genomics. 29(5):114-120, July 2019.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Minami, Hironobu; Sai, Kimie; Saeki, Mayumi; More

Pharmacogenetics and Genomics. 17(7):497-504, July 2007.

Ethanol-metabolizing activities and isozyme protein contents of alcohol and aldehyde dehydrogenases in human liver: phenotypic traits of the ADH1B*2 and ALDH2*2 variant gene alleles

Chiang, Chien-Ping; Lai, Ching-Long; Lee, Shiao-Pieng; More

Pharmacogenetics and Genomics. 26(4):184-195, April 2016.

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

Lewis, Joshua P.; Horenstein, Richard B.; Ryan, Kathleen; More

Pharmacogenetics and Genomics. 23(1):1-8, January 2013.

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics. 27(3):89-100, March 2017.

Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in a Malaysian population

Chong, Huey Yi; Lim, Yi Heng; Prawjaeng, Juthamas; More

Pharmacogenetics and Genomics. 28(2):56-67, February 2018.

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

Hung, Shuen-Iu; Chung, Wen-Hung; Jee, Shiou-Hwa; More

Pharmacogenetics and Genomics. 16(4):297-306, April 2006.

Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation

Behre, Hermann M.; Greb, Robert R.; Mempel, Andrea; More

Pharmacogenetics and Genomics. 15(7):451-456, July 2005.

A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia

Itokawa, Masanari; Yamada, Kazuo; Yoshitsugu, Kiyoshi; More

Pharmacogenetics. 13(5):271-278, May 2003.

Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4)

Urban, Thomas J.; Yang, Chen; Lagpacan, Leah L.; More

Pharmacogenetics and Genomics. 17(9):773-782, September 2007.

Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population

Saksit, Niwat; Tassaneeyakul, Wichittra; Nakkam, Nontaya; More

Pharmacogenetics and Genomics. 27(7):255-263, July 2017.

Thiopurine pathway

Zaza, Gianluigi; Cheok, Meyling; Krynetskaia, Natalia; More

Pharmacogenetics and Genomics. 20(9):573-574, September 2010.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Yasmin; Vizeli, Patrick; Hysek, Cédric M.; More

Pharmacogenetics and Genomics. 26(8):397-401, August 2016.

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver

Girard, Hugo; Court, Michael H; Bernard, Olivier; More

Pharmacogenetics. 14(8):501-515, August 2004.

Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression

Kwan, Patrick; Poon, Wai Sang; Ng, Ho-Keung; More

Pharmacogenetics and Genomics. 18(11):989-998, November 2008.

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

Lubomirov, Rubin; di Iulio, Julia; Fayet, Aurélie; More

Pharmacogenetics and Genomics. 20(4):217-230, April 2010.

The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease

Dideberg, Vinciane; Théâtre, Emilie; Farnir, Frédéric; More

Pharmacogenetics and Genomics. 16(10):727-734, October 2006.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

Chen, Ying; Li, Shuanglian; Brown, Chaline; More

Pharmacogenetics and Genomics. 19(7):497-504, July 2009.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Takahashi, Harumi; Wilkinson, Grant R.; Nutescu, Edith A.; More

Pharmacogenetics and Genomics. 16(2):101-110, February 2006.

Beta2-adrenergic receptor polymorphisms as a determinant of preferential bronchodilator responses to β2-agonist and anticholinergic agents in Japanese patients with chronic obstructive pulmonary disease

Konno, Satoshi; Makita, Hironi; Hasegawa, Masaru; More

Pharmacogenetics and Genomics. 21(11):687-693, November 2011.

HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia

Low, Dyoi E; Nurul-Aain, Ahmad Fauzi; Tan, Wooi Chiang; More

Pharmacogenetics and Genomics. 30(7):153-160, September 2020.

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy

Huang, Ming-Yii; Huang, Meng-Lin; Chen, Ming-Jenn; More

Pharmacogenetics and Genomics. 21(1):18-25, January 2011.

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab

Lee, Janet S.; Wang, Jianmei; Martin, Mitchell; More

Pharmacogenetics and Genomics. 21(7):365-374, July 2011.

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients

Fukudo, Masahide; Yano, Ikuko; Yoshimura, Atsushi; More

Pharmacogenetics and Genomics. 18(5):413-423, May 2008.

Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 −24C>T polymorphism in young and adult patients with epilepsy

Ufer, Mike; Mosyagin, Igor; Muhle, Hiltrud; More

Pharmacogenetics and Genomics. 19(5):353-362, May 2009.